长期腹膜透析包裹性腹膜硬化症风险预测及预防措施  

Risk assessment,prevention and management of encapsulated peritoneal sclerosis in long⁃term peritoneal dialysis patients

作　　者：张志宏(综述) 俞雨生(审校) ZHANG Zhihong;YU Yusheng(National Clinical Research Center of Kidney Disease,Jinling Hospital,Nanjing University School of Medicine,Nanjing 210016,China)

机构地区：[1]东部战区总医院国家肾脏疾病临床研究中心全军肾脏病研究所,南京210016

出　　处：《肾脏病与透析肾移植杂志》2020年第4期381-385,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

摘　　要：包裹性腹膜硬化症(EPS)是长期腹膜透析患者可能出现的严重并发症。EPS起病隐匿,早期诊断困难,缺乏特异性治疗手段,死亡率较高。本文总结现阶段研究进展,综述长期腹膜透析患者EPS风险预测及预防。Encapsulating peritoneal sclerosis(EPS)is a rare complication in long⁃term peritoneal dialysis(PD)patients,and carries significant morbidity and mortality.The pathogenesis of EPS remains elusive,and is hard to be recognized at its early stage.No specific treatment has been developed at the present time.The discussion herein will review the available literature of risk assessment,prevention and management of EPS.

关 键 词：包裹性腹膜硬化症 腹膜透析 风险 

分 类 号：R73[医药卫生—肿瘤]